Ascletis Pharma Reports Promising Phase Ib Results for ASC30 in Obesity Treatment

An announcement from Ascletis Pharma, Inc. ( (HK:1672) ) is now available.

Ascletis Pharma Inc. announced positive interim results from its U.S. Phase Ib trial of ASC30, a potentially first-in-class subcutaneous injection small molecule GLP-1R agonist. The trial demonstrated a 36-day half-life for one formulation, supporting less frequent administration, and showed a favorable safety profile with no serious adverse events. This advancement could enhance Ascletis’ positioning in the obesity treatment market, offering a novel therapeutic option with both oral and injectable formulations.

More about Ascletis Pharma, Inc.

Ascletis Pharma Inc. is a biopharmaceutical company focused on the development of innovative drugs for the treatment of diseases such as obesity. The company specializes in creating small molecule therapeutics, with a particular emphasis on GLP-1 receptor agonists, and operates within the global pharmaceutical market.

YTD Price Performance: 147.51%

Average Trading Volume: 6,073,762

Technical Sentiment Signal: Sell

Current Market Cap: HK$7.21B

For detailed information about 1672 stock, go to TipRanks’ Stock Analysis page.